loading
Myriad Genetics Inc stock is traded at $5.09, with a volume of 1.69M. It is up +3.46% in the last 24 hours and down -29.99% over the past month. Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$4.92
Open:
$4.93
24h Volume:
1.69M
Relative Volume:
0.83
Market Cap:
$386.22M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-3.9154
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+21.48%
1M Performance:
-29.99%
6M Performance:
-66.36%
1Y Performance:
-77.17%
1-Day Range:
Value
$4.93
$5.17
1-Week Range:
Value
$4.17
$5.40
52-Week Range:
Value
$3.8119
$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Name
Name
Myriad Genetics Inc
Name
Phone
801-584-3600
Name
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Name
Employee
2,700
Name
Twitter
@myriadgenetics
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
MYGN's Discussions on Twitter

Compare MYGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
MYGN
Myriad Genetics Inc
5.09 386.22M 823.60M -116.00M -107.30M -1.30
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
401.90 152.06B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
196.02 135.91B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
524.91 41.29B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
115.80 31.79B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
152.32 24.28B 15.50B 1.33B 2.16B 7.34

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-21-25 Downgrade Scotiabank Sector Outperform → Sector Perform
May-08-25 Downgrade Wolfe Research Outperform → Peer Perform
May-07-25 Downgrade Wells Fargo Overweight → Equal Weight
Apr-09-25 Downgrade Guggenheim Buy → Neutral
Mar-12-25 Upgrade Piper Sandler Neutral → Overweight
Feb-12-25 Initiated Craig Hallum Buy
Dec-10-24 Initiated UBS Neutral
Dec-09-24 Downgrade Leerink Partners Outperform → Market Perform
Sep-19-24 Initiated Morgan Stanley Equal-Weight
Aug-28-24 Initiated Wells Fargo Overweight
Jun-27-24 Initiated Scotiabank Sector Outperform
Jun-03-24 Resumed Jefferies Underperform
May-08-24 Upgrade Leerink Partners Market Perform → Outperform
Dec-21-23 Resumed Piper Sandler Neutral
Dec-19-23 Initiated Wells Fargo Equal Weight
Dec-14-23 Initiated Guggenheim Buy
Dec-13-23 Initiated Wolfe Research Outperform
Jul-05-23 Resumed JP Morgan Underweight
May-23-23 Upgrade Goldman Sell → Buy
Jan-18-23 Upgrade Raymond James Mkt Perform → Outperform
Oct-06-22 Initiated Stephens Equal-Weight
Oct-15-21 Resumed Cowen Market Perform
Jun-15-21 Initiated Raymond James Mkt Perform
Jun-03-21 Initiated Goldman Sell
Sep-26-19 Downgrade BofA/Merrill Neutral → Underperform
Aug-14-19 Downgrade Piper Jaffray Overweight → Neutral
Aug-02-19 Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19 Upgrade Barclays Underweight → Equal Weight
Jul-29-19 Downgrade Needham Strong Buy → Hold
Jul-09-19 Downgrade Cowen Outperform → Market Perform
Mar-12-19 Reiterated Needham Strong Buy
Jan-03-19 Initiated Needham Strong Buy
Nov-30-18 Upgrade Goldman Sell → Neutral
Oct-10-18 Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18 Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18 Initiated Goldman Sell
Jan-22-18 Reiterated Barclays Equal Weight
Jan-05-18 Initiated BTIG Research Buy
Oct-02-17 Resumed Leerink Partners Mkt Perform
Aug-09-17 Reiterated Barclays Equal Weight
Feb-08-17 Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17 Initiated Deutsche Bank Sell
Oct-10-16 Downgrade Ladenburg Thalmann Neutral → Sell
View All

Myriad Genetics Inc Stock (MYGN) Latest News

pulisher
Jun 06, 2025

3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - FinancialContent

Jun 06, 2025
pulisher
Jun 05, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Trend Tracker for (MYGN) - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo

Jun 03, 2025
pulisher
Jun 03, 2025

Myriad Genetics (MYGN) Launches FirstGene Multiple Prenatal Screen | MYGN Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Myriad Genetics Launches FirstGene™ Prenatal Screen for Comprehensive Genetic Risk Assessment in One Blood Draw - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Breakthrough Prenatal Screen Combines 4 Tests in 1 Blood DrawNo Father Sample Needed - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Hereditary Testing MarketGlobal Industry Trends, - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

MYGN INVESTOR REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 02, 2025

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Myriad Genetics (MYGN) Reports Promising Results from MONSTAR-SCREEN 3 Study | MYGN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough: Myriad Genetics New Cancer Test Detects Tumors 60% Better Than First-Gen Tests - Stock Titan

Jun 02, 2025
pulisher
May 29, 2025

Ameriprise Financial Inc. Has $2.88 Million Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 29, 2025
pulisher
May 27, 2025

Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025 - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

Myriad Genetics Highlights New Research Advancements and Oncolog - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting | MYGN Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

May 27, 2025
pulisher
May 27, 2025

Man Group plc Makes New $390,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 27, 2025
pulisher
May 26, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire

May 26, 2025
pulisher
May 26, 2025

Deutsche Bank AG Purchases 27,541 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 26, 2025
pulisher
May 25, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out - ACCESS Newswire

May 25, 2025
pulisher
May 25, 2025

Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud - ACCESS Newswire

May 25, 2025
pulisher
May 24, 2025

Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

Scotiabank Downgrades Myriad Genetics (NASDAQ:MYGN) to Sector Perform - Defense World

May 23, 2025
pulisher
May 22, 2025

Microtomes Market Generated Opportunities, Future Scope - openPR.com

May 22, 2025
pulisher
May 22, 2025

Parp Inhibitor Biomarkers Market Generated Opportunities, - openPR.com

May 22, 2025
pulisher
May 22, 2025

BNP Paribas Financial Markets Purchases 23,408 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 22, 2025
pulisher
May 22, 2025

Captrust Financial Advisors Grows Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World

May 22, 2025
pulisher
May 21, 2025

Myriad Genetics Shares Fall After Downgrade From Scotiabank - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 21, 2025
pulisher
May 21, 2025

Genetic Counseling Market Deep Research Report with Forecast by 2032 | Invitae Corporation, Myriad Genetics - openPR.com

May 21, 2025
pulisher
May 21, 2025

Myriad Genetics (MYGN) Faces Downgrade and Price Target Reduction | MYGN Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday - Benzinga

May 21, 2025
pulisher
May 21, 2025

Scotiabank Downgrades Myriad Genetics (MYGN) With Revised Price - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

May 21, 2025
pulisher
May 20, 2025

Scotiabank Downgrades Myriad Genetics (MYGN) Rating | MYGN Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect - ACCESS Newswire

May 20, 2025
pulisher
May 20, 2025

Myriad Genetics (MYGN) Faces Downgrade Amidst Challenging Quarte - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Myriad Genetics (MYGN) Faces Price Target Cut After Q1 Miss | MY - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Levi & Korsinsky Investigates Possible Securities Fraud by Myriad Genetics, Inc. (MYGN) - ACCESS Newswire

May 19, 2025
pulisher
May 19, 2025

Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp - Yahoo Finance

May 19, 2025

Myriad Genetics Inc Stock (MYGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
diagnostics_research DGX
$174.34
price up icon 0.40%
diagnostics_research WAT
$351.17
price up icon 1.40%
diagnostics_research LH
$253.97
price up icon 0.72%
$163.76
price down icon 1.06%
diagnostics_research MTD
$1,184.34
price up icon 1.69%
diagnostics_research IQV
$152.32
price up icon 3.36%
Cap:     |  Volume (24h):